Neurocrine reports positive Phase II trial results for NBI-1065845
Neurocrine Biosciences has announced positive topline data from its Phase II SAVITRI study, evaluating the efficacy and safety of NBI-1065845 in adults with major depressive disorder (MDD). NBI-1065845 is a potential first-in-class, investigational alpha- …